CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2016	Jun. 30, 2015
Cash flows from operating activities
Net (loss) income	$ (113,363)	$ 130,460
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	113,141	60,375
Deferred income taxes	32,906	(17,509)
Share-based compensation expense related to equity incentive plans	59,579	14,112
Excess tax benefit from share-based compensation	0	(263)
Amortization of debt discount on convertible debentures	12,106	11,772
Amortization of debt issuance costs	1,057	958
Losses on equity method investments	56	177
Gains on sale of assets	(61)	(560)
Loss on write-down of fixed assets	269	0
Impairment of intangible assets	1,984	0
Realized losses (gains) on available-for-sale investment	82	(13,959)
Realized gains on equity method investment	(468)	(2,225)
Amortization of premium on available-for-sale investments	13	2,396
Changes in operating assets and liabilities, excluding impact of acquisitions:
Increase in accounts receivable	(9,901)	(3,096)
Decrease (increase) in inventories	121,102	(23,893)
Increase in deferred income on shipments to distributors	29,739	1,401
(Decrease) increase in accounts payable and accrued liabilities	(18,000)	16,157
Change in other assets and liabilities	(12,270)	5,225
Operating cash flows related to discontinued operations	5,996	0
Net cash provided by operating activities	223,967	181,528
Cash flows from investing activities
Purchases of available-for-sale investments	(25)	(570,501)
Sales and maturities of available-for-sale investments	470,551	433,446
Sale of equity method investment	468	2,667
Acquisition of Atmel, net of cash acquired	(2,747,516)	0
Purchase of additional controlling interest in ISSC	0	(18,051)
Investments in other assets	(765)	(1,766)
Proceeds from sale of assets	52	627
Capital expenditures	(18,494)	(33,611)
Net cash used in investing activities	(2,295,729)	(187,189)
Cash flows from financing activities:
Repayments of revolving loan under credit facility	(602,000)	(110,000)
Proceeds from borrowings on revolving loan under credit facility	1,280,000	145,000
Deferred financing costs	0	(406)
Payment of cash dividends	(77,237)	(72,331)
Proceeds from sale of common stock	4,630	3,497
Tax payments related to shares withheld for vested restricted stock units	(25,183)	(4,464)
Capital lease payments	(195)	(166)
Excess tax benefit from share-based compensation	0	263
Net cash provided by (used in) financing activities	580,015	(38,607)
Effect of foreign exchange rate changes on cash and cash equivalents	(478)	0
Net decrease in cash and cash equivalents	(1,492,225)	(44,268)
Cash and cash equivalents at beginning of period	2,092,751	607,815
Cash and cash equivalents at end of period	$ 600,526	$ 563,547